◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › C › CTMX

CytomX Therapeutics Inc (CTMX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

CytomX Therapeutics Inc (CTMX) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 69 employees. Its market capitalization is roughly $808 million. In the fiscal year ended 2025-12-31, CTMX reported $76M in revenue and ($17M) in net income.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Interactive charts & full statements → Open the CTMX valuation workbench →

CTMX Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Revenue$18M$76M$138M$101M$53M$70M$68M$57M$60M$72M$15M$8M$5M$1M
Gross Profit$18M$76M$138M$101M$53M$70M$68M$57M$60M$72M$15M$8M$5M$1M
Gross Margin %100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)($88M)($22M)$25M($6M)($101M)($84M)($81M)($111M)($78M)($46M)($60M)($33M)($30M)($15M)
Operating Margin %-488.9%-29.3%18.1%-6.4%-190.6%-120.4%-117.7%-192.9%-130.9%-64.6%-396.1%-430.5%-586.3%-1684.2%
Net Income($80M)($17M)$32M($1M)($97M)($81M)($65M)($102M)($85M)($43M)($59M)($35M)($30M)($15M)
Net Margin %-444.4%-22.8%23.1%-0.6%-183.0%-115.9%-94.7%-177.8%-142.2%-60.2%-391.5%-458.7%-597.0%-1705.3%
EBITDA($78M)($16M)$34M$5M($99M)($81M)($78M)($108M)($76M)($42M)($58M)($32M)($29M)($14M)
Earnings Per Share (EPS)$-0.44$-0.13$0.38$-0.01$-1.48$-1.26$-1.40$-2.26$-2.03$-1.16$-1.63$-1.00$-0.87$-15.32
Shares Outstanding (M)219M138M85M74M66M64M46M45M42M37M36M35M—1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTMX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$1M$10M$1M$6M$19M$51M$38M$33M
Gross Profit$1M$10M$1M$6M$19M$51M$38M$33M
Gross Margin %100.0%97.5%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)($24M)($20M)($28M)($16M)($1M)$23M$18M$4M
Operating Margin %-1677.1%-191.8%-4213.0%-264.4%-6.9%44.4%46.4%12.3%
Net Income($21M)($18M)($27M)($14M)$0M$24M$19M$6M
Net Margin %-1457.4%-177.9%-3998.5%-238.6%-0.8%46.2%49.5%17.2%
EBITDA($20M)($18M)($26M)($14M)$0M$24M$19M$6M
Earnings Per Share (EPS)$-0.09$-0.10$-0.16$-0.09$-0.00$0.27$0.24$0.07
Shares Outstanding (M)219M177M170M165M129M87M80M85M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTMX Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Cash from Operations (CFO)($83M)($76M)($86M)($56M)($111M)($119M)$5M($140M)($76M)$170M($2M)($27M)$32M($8M)
Capital Expenditures (CapEx)$0M$0M$0M$1M$2M$2M$2M$3M$4M$2M$2M$2M$2M$1M
Free Cash Flow (FCF)($83M)($76M)($87M)($57M)($113M)($121M)$3M($144M)($79M)$169M($4M)($29M)$30M($9M)
FCF Margin %-461.1%-99.5%-62.7%-56.2%-211.7%-173.4%4.3%-250.4%-133.3%235.7%-28.0%-376.1%593.6%-984.2%
Dividends Paid—$3M———————$0M$0M$7M——

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTMX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($18M)($26M)($23M)($16M)($16M)($21M)($20M)($21M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($18M)($26M)($23M)($16M)($16M)($21M)($20M)($21M)
FCF Margin %-1274.2%-249.1%-3536.1%-262.9%-84.6%-41.6%-52.5%-62.1%
Dividends Paid——$3M—————

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTMX Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Assets$381M$152M$121M$202M$261M$339M$359M$341M$457M$398M$199M$197M$73M$14M
Cash & Cash Equivalents$17M$13M$38M$17M$194M$206M$192M$188M$248M$178M$105M$60M$64M$9M
Total Liabilities$79M$53M$121M$249M$347M$250M$366M$290M$326M$328M$121M$71M$152M$58M
Total Debt (Short + Long-Term)$1M$4M$5M$5M$4M$4M$3M$3M$13M$0M$0M$0M$3M$4M
Total Shareholders' Equity$302M$99M$0M($47M)($86M)$89M($8M)$51M$131M$70M$78M$126M($79M)($44M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTMX viewer.

Other Companies in BIOTECHNOLOGY

← CTMAAll “C” companiesCTNM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.